Learn More
e21105 Background: Worse prognosis of the presence of CTCs in peripheral blood has been demonstrated in MBC and have potencial to influence the clinical management for pts. Bevacizumab (B) in(More)
1022 Background: Appropriate determination of immunohistochemistry (IHC) to define EBC subtypes is crucial for an adequate treatment recommendation. A number of studies have raised questions about(More)
  • 1